Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine
Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
Drug resistance in multiple myeloma
Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
To elucidate the mechanisms underlying relapse from chemotherapy in multiple myeloma,
we performed a longitudinal study of 33 patients entered into Total Therapy protocols …
we performed a longitudinal study of 33 patients entered into Total Therapy protocols …
Next-generation sequencing: advances and applications in cancer diagnosis
S Serratì, S De Summa, B Pilato, D Petriella… - OncoTargets and …, 2016 - Taylor & Francis
Technological advances have led to the introduction of next-generation sequencing (NGS)
platforms in cancer investigation. NGS allows massive parallel sequencing that affords …
platforms in cancer investigation. NGS allows massive parallel sequencing that affords …
Bortezomib for the treatment of hematologic malignancies: 15 years later
Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome
pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in …
pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in …
Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability
Multiple myeloma (MM) is a largely incurable haematological malignancy defined by the
clonal proliferation of malignant plasma cells (PCs) within the bone marrow. Clonal …
clonal proliferation of malignant plasma cells (PCs) within the bone marrow. Clonal …
The emerging roles of NGS in clinical oncology and personalized medicine
Next-generation sequencing (NGS) has been increasingly popular in genomics studies over
the last decade, as new sequencing technology has been created and improved. Recently …
the last decade, as new sequencing technology has been created and improved. Recently …
[HTML][HTML] Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in …
The emergence of treatment resistant sub-clones is a key feature of relapse in multiple
myeloma. Therapeutic attempts to extend remission and prevent relapse include maximizing …
myeloma. Therapeutic attempts to extend remission and prevent relapse include maximizing …
Genome instability in multiple myeloma: Facts and factors
Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
[HTML][HTML] IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
S Barrio, U Munawar, YX Zhu, N Giesen, CX Shi… - …, 2020 - ncbi.nlm.nih.gov
Cereblon (CRBN), a target of immunomodulatory drugs (IMiD), forms the CRL4CRBN E3
ubiquitin ligase (CRL4) complex with DDB1, CUL4B and ROC1. 1, 2 Under the influence of …
ubiquitin ligase (CRL4) complex with DDB1, CUL4B and ROC1. 1, 2 Under the influence of …